INTRODUCTION
Adrenoieukodystrophy (ALD) (McKusick # 300100) is an Xlinked peroxisomal disorder characterized by progressive demyelination of the central nervous system and adrenal insufficiency (1) . ALD is associated with an accumulation of very long chain fatty acids (VLCFA) in white matter, adrenal glands, flbroblasts and plasma due to an impairment of /3-oxidation of these fatty acids in peroxisomes (1) . The normal oxidation of VLCFA-CoA in fibroblasts from ALD patients suggested that the gene coding for the VLCFA-CoA synthetase could be a candidate gene for ALD (2) (3) (4) (5) (6) (7) . We recently identified a candidate ALD gene by positional cloning strategies (8) . Deletions were found in 6/85 unrelated ALD patients. Some of these deletions were small and non-overlapping.
The gene which we have characterized has an open reading frame of 2235 bases which encodes a 745 amino acid protein with 38.5 % amino acid identity and 78.9% similarity to a human 70 Kd peroxisomal membrane protein (PMP) involved in peroxisomal biogenesis (9, 10) . This gene had however no homology to a recendy cloned rat gene for long-chain acyl-CoA synthetase (11) . Therefore, we sought additional genetic evidence that this putative gene is responsible for ALD. We identified four ALD patients who lacked transcripts on Northern blot and one who had a smaller 4.0 kb transcript. A sixth patient with a transcript indistinguishable in size from controls had a missense mutation predicting a Glu-291-Lys substitution in a conserved region of the ALD protein.
RESULTS
Northern blot analyses using cDNA probes (Exl3, Ex3 or H8) reveal in normal fibroblasts a 4.2 kb transcript ( Figure 1, lane  N) , similar in size to die major transcript observed in normal liver, skeletal muscle, testis, adrenal gland and brain tissues (8) . The last ALD patient (GG) had a transcript indistinguishable in size from control ( Figure 1 lane 2) . The TA25 probe which includes the 5' end of the ALD gene (8) detected in diis patient an abnormal 1.9 kb TaqI restriction DNA fragment, while a 2.1 kb DNA fragment was observed in control males (not shown). As no abnormally sized BamHI, Hindm or EcoRI restriction DNA fragments (see Figure 1C in reference 8 for a general map of the ALD gene) were detected in tiiis patient using the same TA25 probe, this change predicted mat a novel TaqI restriction site was created in exon 1. We therefore designed primers witiiin this exon and intron 1 to amplify a 437 bp fragment directly from the DNA of this patient, his heterozygous motfier, his non affected brodier and normal controls (Figure 2A ). The PCR-amplified fragment was digested by TaqI to confirm that it contains the novel TaqI restriction site. Two fragments of about 200 bp were observed in the ALD patient but were absent in his non affected brother and normal controls ( Figure 2B ). As expected, the mother showed a normal 437 bp fragment and the two abnormal 200 bp fragments ( Figure 2B ). The normal and abnormal 437 bp fragments from this ALD patient and his heterozygous mother were subcloned and sequenced. A G-A mutation at base 1258 was found in the ALD allele and in one allele of his mother, converting a glutamic acid to lysine at residue 291 ( Figure 3A) . This mutation was absent in his unaffected brother and in normal * To whom correspondence should be addressed The same filter as in A, stripped of probe and rehybridized to a human /3-actin probe.
•#• controls. Although we cannot exclude a rare polymorphic variant, this mutation creating a novel TaqI restriction site was absent in 82 control males and in 87 unrelated other ALD patients, as determined by Southern blot analysis.
DISCUSSION
We found that the transcript of the putative ALD gene was absent or altered in size in 4 ALD patients with deletion, and absent in a patient with a point mutation or a small insertion/deletion not detectable on Southern blot. In another patient with a normal transcript, we report the first missense mutation of the ALD gene. This mutation generates a non-conservative change in a stretch of 8 amino acids which is identical between the ALD protein (position 289-296) and the 70 kD PMP (position 275-282) (8, 10) (Figure 3B ). This stretch is the longest conserved one between the amino-terminal half of the two proteins (8) and is located between the fourth and the fifth transmembrane segments. Although confirmation of an abnormal function of ALD protein resulting from this mutation will require in vitro expression studies, this result as well as the abnormal messenger RNA expression in other ALD patients provide definitive evidence that the gene we identified is indeed responsible for ALD.
MATERIAL AND METHODS
Probes TA25 (2.1 kb) is a TaqI digested DNA fragment derived from subcloning of cosmid Qc 11H12 (8) that includes exon 1. Ex 13 (amino acid residues 279-482) and Ex 3 (amino acid residues 478-648) are cDNAs obtained from exonconnection (8) . H8 is a cDNA clone that encompasses 386 bp of 5' untranslated region and amino acid residues 1 -660. Probes were labeled with [a-32 P]dCTP using the hexamer labelling method (12) .
Northern blot
Total RNA from fibroblast cell lines was extracted using guanidium isothyocyanate followed by centrifugation through caesium chloride as described (13) . Twenty micrograms of RNA was modified by glyoxalation (14) , fractionated through 1 % agarose gels in 10 mM sodium phosphate (pH 7.0) and transferred to nylon membrane (Hybond N + , Amersham) overnight in 10XSSC. The RNA was fixed by alkali fixation (50 mM NaOH) and hybridizations were performed as described previously (15) . Filters were washed with 5 xSSC, 0.1 % SDS at 55°C, and then the SSC concentration was lowered according to the level of background with a final wash in 0.2XSSC, 0.1 xSDS. The membranes were exposed at -70°C to X-ray film 12 days (Exl3, Ex3 or H8 probes) or 12 hours (/3-actin probe). RNA markers (Gibco BRL) were used as size standard.
Genomic DNA PCR
A 437 bp genomic segment starting in exon 1 at position 1029 of the published cDNA sequence (8) and ending within intron 1 (C.S. et al., in preparation) was PCR amplified using 1 pg of genomic DNA in 50 fi\ of 10 mM Tris-Cl pH 8.3, 50 mM KQ, 1.5 mM MgCl 2 , 200 ^M each dNTP, 0.2 U Amplitaq (PerkinElmer) and 50 pmoles of primers. Primers used were 5'-CCTGACCAAGCC-ACTCCTGGA-3' and 5'-CTGAGTCCACGGCTGCCCAAA-3\ PCR was performed in a Perkin Elmer Cetus DNA thermal cycler for 30 cycles (each cycle was 94°C for 1 minute, 58°C for 1 minute and 72°C for 2 minutes). One third of the reaction was loaded on a 2% agarose gel in 40 mM Tris-acetate, 1 mM EDTA.
Sequencing
The genomic amplified fragments were excised from LMP agarose, cloned in Bluescript KS+ using the PCR-Script kit (Stratagene) and sequenced with Downloaded from https://academic.oup.com/hmg/article-abstract/2/11/1949/690757 by guest on 20 November 2018 Sequenase 2.0 (US Biochemical). Sequences were determined three times on both strands. Primers labelled with a 33 S dATP were 5'-ATTAACCCTCACTAAA-G-3' and 5'-GCTGATGCCAAAGAGGTGTGG-3'.
